Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 709-713

  Gadel, Sarah ^a   Crafford, Amanda ^a   Regina, Karen ^a   Kharasch, Evan D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2B6.1; CYTOCHROME P450 2B6.6; METHADONE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; CATALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYP2B6.6 GENE; DEMETHYLATION; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; INSECT CELL; LIVER MICROSOME; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; STEREOCHEMISTRY; WILD TYPE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; HUMANS; ISOENZYMES; METHADONE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; STEREOISOMERISM;

EID: 84875820989     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050625     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention (CDC) (2012) Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 61: 493-497.
2. Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, Ishii I, Ishikawa T, and Kitada M (2011) Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab Dispos 39: 2045-2048.
3. Bunten H, Liang WJ, Pounder D, Seneviratne C, and Osselton MD (2011) CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 16:142-144.
4. Chang Y, Fang WB, Lin SN, and Moody DE (2011) Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 108:55-62.
5. Chung JY, Cho JY, Lim HS, Kim JR, Yu KS, Lim KS, Shin SG, and Jang IJ (2011) Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos 39:92-97.
6. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, and Eap CB (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668-681.
7. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, and Eap CB (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593-604.
8. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, and Zanger UM (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547-558.
9. Eap CB, Crettol S, Rougier JS, Schläpfer J, Sintra Grilo L, Déglon JJ, Besson J, Croquette-Krokar M, Carrupt PA, and Abriel H (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81:719-728.
10. Ferrari A, Coccia CP, Bertolini A, and Sternieri E (2004) Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551-559.
11. Gerber JG, Rhodes RJ, and Gal J (2004) Stereoselective metabolism of methadone Ndemethylation by cytochrome P4502B6 and 2C19. Chirality 16:36-44.
12. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, and Acosta EP (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400.
13. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, and Court MH (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14: 225-238.
14. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, and Zanger UM (2008) Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6 6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325:284-292.
15. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, and Daar ES, et al. (2012) Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 22:858-867.
16. Honda M, Muroi Y, Tamaki Y, Saigusa D, Suzuki N, Tomioka Y, Matsubara Y, Oda A, Hirasawa N, and Hiratsuka M (2011) Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether. Drug Metab Dispos 39:1860-1865.
17. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, and Lane HY (2011) Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12:1525-1533.
18. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, and Ando M (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31: 398-403.
19. Kharasch ED, Bedynek PS, Hoffer C, Walker A, and Whittington D (2012) Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology 116:432-447.
20. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, and Hoffer C (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 84:497-505.
21. Kharasch ED, Hoffer C, Whittington D, and Sheffels P (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269.
22. Kharasch ED and Stubbert K (2013) Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol, in press.
23. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
24. Levran O, Peles E, Hamon S, Randesi M, Adelson M, and Kreek MJ (2011) CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol [published ahead of print].
25. McCance-Katz EF, Sullivan LE, and Nallani S (2010) Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 19:4-16.
26. Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, and Zhou SF (2009) Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 10:730-753.
27. Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, and Totah RA (2012) Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab Dispos 40:54-63.
28. Sharma A, Tallchief D, Blood J, Kim T, London A, and Kharasch ED (2011) Perioperative pharmacokinetics of methadone in adolescents. Anesthesiology 115:1153-1161.
29. Totah RA, Allen KE, Sheffels P, Whittington D, and Kharasch ED (2007) Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 321:389-399.
30. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, and Kharasch ED (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363-374.
31. Turpeinen M and Zanger UM (2012) Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact 27:185-197.
32. van Heeswijk R, Vandevoorde A, Verboven P, Boogaerts G, De Paepe E, van Solingen-Ristea R, Garg V, and Beumont M (2011) Pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. J Hepatol 54:S491-S492.
33. Vourvahis M, Wang R, Gruener DM, Bruce RD, Haider S, and Tawadrous M (2012) Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug Alcohol Depend 126:183-188.
34. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
35. Wang SC, Ho IK, Tsou HH, Tian JN, Hsiao CF, Chen CH, Tan HK, Lin L, Wu CS, and Su LW, et al. (2011) CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 31:463-469.
36. Watanabe T, Sakuyama K, Sasaki T, Ishii Y, Ishikawa M, Hirasawa N, and Hiratsuka M (2010) Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenet Genomics 20:459-462.
37. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, and Rane A (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3: 53-61.
38. Xu C, Ogburn ET, Guo Y, and Desta Z (2012) Effects of the CYP2B6 6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos 40:717-725.
39. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743-759.
40. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, and Hollenberg PF (2011) Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J Pharmacol Exp Ther 338:803-809.